By Sabela Ojea
Sangamo Therapeutics said the Food and Drug Administration has cleared its investigational new drug application for its ST-400 treatment for intractable pain due to idiopathic small fiber neuropathy.
Shares rise 10%, to $2.14, in after-hours trading Tuesday. Through the close, the stock has more than tripled since the beginning of the year.
The genomic-medicine company said it is preparing to initiate enrollment of patients in the phase 1/2 study for the ST-503 program, an investigational epigenetic regulator.
Overall, the company plans to initiate patient enrollment in mid-2025.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
November 19, 2024 16:41 ET (21:41 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。